Filing summary
Entity and period: The supplied filing is Novus Therapeutics, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2019 (ticker NVUS), not an Eledon Pharmaceuticals filing. The filing describes a clinical-stage specialty pharmaceutical company developing ENT treatments.
Financial performance and position
| Metric | Q1 2019 | Q1 2018 / comparison |
|---|---|---|
| Revenue | No product revenue | No product revenue reported |
| Research and development expense | $2.989 million | $1.097 million; up 172% |
| General and administrative expense | $1.886 million | $1.698 million; up 11% |
| Total operating expenses | $4.875 million | $2.795 million; up 74% |
| Net loss | $4.881 million | $2.806 million |
| Net loss per share | $0.52 | $0.36 |
| Operating cash flow | $(4.023) million | $(2.271) million |
| Cash at quarter-end | $9.056 million | $12.972 million at December 31, 2018 |
Margins are not meaningful because the company reported no product revenue. At March 31, 2019, total assets were $13.451 million, current liabilities $3.241 million, working capital $7.1 million, and stockholders’ equity $9.929 million. The filing reports no borrowings or committed credit facilities; lease liabilities totaled $451,000. Accumulated deficit was $46.452 million.
Material changes and developments
- Research and development expense increased $1.892 million year over year, principally from higher OP0201 clinical costs ($1.6 million), formulation development ($266,000), and personnel costs, partly offset by lower consulting expense.
- Management attributed the $188,000 increase in general and administrative expense to personnel and stock compensation and higher litigation costs, partly offset by lower other costs.
- Operating cash use increased year over year. Q1 2019 financing provided $107,000 from at-the-market stock sales, versus $7.491 million in Q1 2018.
- On April 30, 2019, after quarter-end, the company agreed to sell 3,449,112 common shares for approximately $10.7 million gross proceeds. The concurrent private placement included Series A and Series B warrants, each for up to 3,449,112 shares at $4.00; the Series B warrants become exercisable only upon exercise of the Series A warrants.
Outlook, risks, and unusual items
- Management concluded that substantial doubt existed about the company’s ability to continue as a going concern for the 12 months following issuance of the financial statements. It said cash was insufficient to fund operations through that period without additional financing.
- The company expected continuing losses and increased R&D spending as it advanced OP0201. It was conducting an exploratory Phase 2a study in infants and children with acute otitis media; later Phase 2 and Phase 3 studies were planned, subject to results and financing.
- Management was pursuing strategic alternatives and implementing cost reductions beginning in the first half of 2019. Further cuts could include personnel costs and delaying or curtailing R&D, potentially affecting planned objectives.
- The April financing provides additional cash after quarter-end but involves share dilution and warrants; the filing does not state that it eliminates the going-concern uncertainty.
- The company had no approved products or product sales. Key risks include clinical and regulatory failure, financing availability, manufacturing scale-up and reliance on sole suppliers, and potential dilution from future capital raises.
- Tokai-related shareholder securities litigation remained unresolved. The company stated it could not estimate the possible loss; no contingent liability was accrued at March 31, 2019. A $300,000 OP0201 milestone payment was made in March following first patient enrollment in a Phase 2 study.
Important facts for investors to verify
- Confirm the intended issuer: the supplied 10-Q is for Novus Therapeutics, Inc., not Eledon Pharmaceuticals, Inc.
- Review the status, enrollment, results, and anticipated cost of the OP0201 Phase 2a study and any subsequent trial plans.
- Assess post-quarter cash and runway after the April 30 offering, including offering costs, warrant terms, and potential dilution.
- Track cost-reduction and strategic-alternative plans, and whether management’s going-concern assessment has changed.
- Monitor the Tokai shareholder litigation and any developments that could create a material liability.